Holen Sie sich die Stockscreener-App
4.00
0.00%
0.00
Schlusskurs vom Vortag:
$4.00
Offen:
$4
24-Stunden-Volumen:
69,601
Relative Volume:
0.25
Marktkapitalisierung:
$27.54M
Einnahmen:
$5.21M
Nettoeinkommen (Verlust:
$-26.35M
KGV:
-0.1247
EPS:
-32.0862
Netto-Cashflow:
$-20.84M
1W Leistung:
+0.50%
1M Leistung:
-25.79%
6M Leistung:
+620.46%
1J Leistung:
+1,040%
1-Tages-Spanne:
$3.88
$4.1299
1-Wochen-Bereich:
$3.70
$4.1299
52-Wochen-Spanne:
$0.129
$8.00
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
4.00 | 27.54M | 5.21M | -26.35M | -20.84M | -32.09 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics subsidiary enrolls in Medicare program - Investing.com
PSTV Should I Buy - Intellectia AI
PLUS THERAPEUTICS INC (PSTV) Stock Chart - ChartMill
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J - Moomoo
Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) director converts 922 RSUs into common stock - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting - Stock Titan
PLUS Therapeutics (PSTV) CFO converts RSUs into 2,985 common shares - Stock Titan
[Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Plus Therapeutics provides mid-year business update including corporate rebranding - MSN
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com UK
Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress - marketscreener.com
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - Yahoo Finance
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY By Investing.com - Investing.com South Africa
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress - Quiver Quantitative
Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3 - Stock Titan
Plus Therapeutics rebrands as Cerenome, affirms 2026 milestones, and reports CNSide commercial progress - Pluang
Price to earnings forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBITDA forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to EBIT forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Price to sales forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Enterprise value to revenue forward of PLUS THERAPEUTICS, Inc. – NASDAQ:PSTV - TradingView
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM: PSTV) added to Russell Microcap Index - marketscreener.com
Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Plus Therapeutics, Inc. Actuals & Estimates (DUS:XMP1) - TradingView
XMP1 Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (GETTEX:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (FWB:XMP1) - TradingView
Plus Therapeutics, Inc. Actuals & Estimates (NASDAQ:PSTV) - TradingView
CNSide signs coverage deal with Elevance Health for 45.4M - Investing.com UK
Plus Therapeutics wins Elevance Health coverage deal - MSN
PSTV Forecast — Price Target — Prediction for 2027 - TradingView
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - The Manila Times
Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay - Quiver Quantitative
Plus Therapeutics Secures National Coverage Agreement with - GlobeNewswire
Plus Therapeutics (PSTV) reports Q1 loss, tops revenue estimates - MSN
Plus Therapeutics to Provide Business Update Call on June 30, 2026 - Sahm
Plus Therapeutics to detail CNSide launch, Reyobiq plan June 30 - Stock Titan
Plus Therapeutics Inc (PSTV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Plus Therapeutics Inc (PSTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Plus Therapeutics Inc (PSTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Plus Therapeutics Inc (PSTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Plus Therapeutics Inc (PSTV) Institutional Confidence - TradingKey
Plus Therapeutics Inc (PSTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Plus Therapeutics Inc (PSTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Plus Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital - Moomoo
PSTV Maintained by Ascendiant Capital -- Price Target Lowered to $57.00 - GuruFocus
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):